Skip to main content
Watch Insiders
DNLIHealthcare

Denali Therapeutics Inc (DNLI) Insider Trading

In the last 90 days, 3 Denali Therapeutics Inc (DNLI) insiders reported no open-market purchases and 4 sales totaling $435,303. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 4, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 4, 2026Peter Scott ChinChief Medical OfficerSale1,654$22.29$36,868
Sep 2, 2026Nancy ThornberryCorporate insiderSale11,439$22.90$261,928
Sep 1, 2026Alexander O. SchuthCOFO and SecretarySale2,768$23.44$64,882
Aug 11, 2026Alexander O. SchuthCOFO and SecretarySale2,857$25.07$71,625

Common questions

DNLI insider trading FAQ

Are DNLI insiders buying or selling?
Over the last 90 days, DNLI insiders were net sellers, reporting $0.00 of open-market purchases and $435,303 of sales.
When was the last DNLI insider purchase?
No open-market insider purchase of Denali Therapeutics Inc stock was reported in the last 90 days.
Where does DNLI insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Denali Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.